About
Develops lipid nanoparticle (LNP) delivery technologies and customized formulation solutions to enable nucleic acid medicines — including mRNA, siRNA and DNA — to reach extrahepatic tissues. Works with partners on co-development of scalable, long-circulating LNP platforms, novel ionizable lipids and mRNA modifications for therapeutic programs.
Explore NanoVation Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.